Eosinophil and Mast Cell Siglecs: From Biology to Drug Target

Overview

Journal J Leukoc Biol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2020 Jan 23

PMID 31965606

Citations 32

Authors

Jeremy A OSullivan

Alan T Chang

Bradford A Youngblood

Bruce S Bochner

Affiliations

Soon will be listed here.

Abstract

Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit.

Citing Articles

Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.

Zhong X, DAntona A, Rouse J Int J Mol Sci. 2024; 25(22).

PMID: 39596031 PMC: 11594235. DOI: 10.3390/ijms252211962.

Sialic acid in the regulation of blood cell production, differentiation and turnover.

Irons E, Gc S, Lau J Immunology. 2024; 172(4):517-532.

PMID: 38503445 PMC: 11223974. DOI: 10.1111/imm.13780.

Sequence variety in the CC' loop of Siglec-8/9/3 determines the recognitions to sulfated oligosaccharides.

Wang Y, Peng Y, Long R, Shi P, Zhang Y, Kong D Comput Struct Biotechnol J. 2023; 21:4159-4171.

PMID: 37675287 PMC: 10477811. DOI: 10.1016/j.csbj.2023.08.014.

Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.

OSullivan J, Youngblood B, Schleimer R, Bochner B Semin Immunol. 2023; 69:101799.

PMID: 37413923 PMC: 10528103. DOI: 10.1016/j.smim.2023.101799.

Siglec-9 is an inhibitory receptor on human mast cells in vitro.

Miralda I, Samanas N, Seo A, Foronda J, Sachen J, Hui Y J Allergy Clin Immunol. 2023; 152(3):711-724.e14.

PMID: 37100120 PMC: 10524464. DOI: 10.1016/j.jaci.2023.04.007.

References

Hudson S, Herrmann H, Du J, Cox P, Haddad E, Butler B . Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J Clin Immunol. 2011; 31(6):1045-53. PMC: 3329870. DOI: 10.1007/s10875-011-9589-4. View

Whitney G, Wang S, Chang H, Cheng K, Lu P, Zhou X . A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. Eur J Biochem. 2001; 268(23):6083-96. DOI: 10.1046/j.0014-2956.2001.02543.x. View

Tateno H, Crocker P, Paulson J . Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology. 2005; 15(11):1125-35. DOI: 10.1093/glycob/cwi097. View

Nutku-Bilir E, Hudson S, Bochner B . Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways. Am J Respir Cell Mol Biol. 2007; 38(1):121-4. PMC: 2176128. DOI: 10.1165/rcmb.2007-0154OC. View

Youngblood B, Brock E, Leung J, Falahati R, Bochner B, Rasmussen H . Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis. JCI Insight. 2019; 4(19). PMC: 6795394. DOI: 10.1172/jci.insight.126219. View

Barnig C, Alsaleh G, Jung N, Dembele D, Paul N, Poirot A . Circulating Human Eosinophils Share a Similar Transcriptional Profile in Asthma and Other Hypereosinophilic Disorders. PLoS One. 2015; 10(11):e0141740. PMC: 4629890. DOI: 10.1371/journal.pone.0141740. View

Kiwamoto T, Brummet M, Wu F, Motari M, Smith D, Schnaar R . Mice deficient in the St3gal3 gene product α2,3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation. J Allergy Clin Immunol. 2013; 133(1):240-7.e1-3. PMC: 3874253. DOI: 10.1016/j.jaci.2013.05.018. View

McMillan S, Sharma R, Richards H, Hegde V, Crocker P . Siglec-E promotes β2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung. J Biol Chem. 2014; 289(29):20370-6. PMC: 4106349. DOI: 10.1074/jbc.M114.574624. View

Na H, Hamilton R, Klion A, Bochner B . Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8. J Immunol Methods. 2012; 383(1-2):39-46. PMC: 3411856. DOI: 10.1016/j.jim.2012.05.017. View

10.

von Gunten S, Vogel M, Schaub A, Stadler B, Miescher S, Crocker P . Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol. 2007; 119(4):1005-11. DOI: 10.1016/j.jaci.2007.01.023. View

11.

Spence S, Greene M, Fay F, Hams E, Saunders S, Hamid U . Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci Transl Med. 2015; 7(303):303ra140. DOI: 10.1126/scitranslmed.aab3459. View

12.

Macauley M, Crocker P, Paulson J . Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014; 14(10):653-66. PMC: 4191907. DOI: 10.1038/nri3737. View

13.

Youngblood B, Brock E, Leung J, Falahati R, Bryce P, Bright J . AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. Int Arch Allergy Immunol. 2019; 180(2):91-102. PMC: 6878738. DOI: 10.1159/000501637. View

14.

Patnode M, Cheng C, Chou C, Singer M, Elin M, Uchimura K . Galactose 6-O-sulfotransferases are not required for the generation of Siglec-F ligands in leukocytes or lung tissue. J Biol Chem. 2013; 288(37):26533-45. PMC: 3772201. DOI: 10.1074/jbc.M113.485409. View

15.

Yokoi H, Myers A, Matsumoto K, Crocker P, Saito H, Bochner B . Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy. 2006; 61(6):769-76. DOI: 10.1111/j.1398-9995.2006.01133.x. View

16.

Propster J, Yang F, Rabbani S, Ernst B, Allain F, Schubert M . Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8. Proc Natl Acad Sci U S A. 2016; 113(29):E4170-9. PMC: 4961179. DOI: 10.1073/pnas.1602214113. View

17.

Suzukawa M, Miller M, Rosenthal P, Cho J, Doherty T, Varki A . Sialyltransferase ST3Gal-III regulates Siglec-F ligand formation and eosinophilic lung inflammation in mice. J Immunol. 2013; 190(12):5939-48. PMC: 3679360. DOI: 10.4049/jimmunol.1203455. View

18.

Robida P, Puzzovio P, Pahima H, Levi-Schaffer F, Bochner B . Human eosinophils and mast cells: Birds of a feather flock together. Immunol Rev. 2018; 282(1):151-167. PMC: 5812359. DOI: 10.1111/imr.12638. View

19.

OReilly M, Paulson J . Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci. 2009; 30(5):240-8. PMC: 2830709. DOI: 10.1016/j.tips.2009.02.005. View

20.

Kardava L, Moir S, Wang W, Ho J, Buckner C, Posada J . Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest. 2011; 121(7):2614-24. PMC: 3127436. DOI: 10.1172/JCI45685. View